Mangoceuticals, Inc.
2.0700-0.07 (-3.27%)
Oct 28, 4:00:01 PM EDT · NasdaqCM · MGRX · USD
Key Stats
Market Cap
23.67MP/E (TTM)
-Basic EPS (TTM)
-3.54Dividend Yield
0%Recent Filings
8-K
Executive equity grants announced
Mangoceuticals' board granted CEO Jacob Cohen 500,000 common shares as a 2025 bonus and options for 2 million more at $2.30 strike, vesting over 18 months with accelerated triggers on termination without cause or change of control. CFO Eugene Johnston received 100,000 shares for his services, while directors Kenny Myers, Alex Hamilton, and Lorraine D'Alessio each got 100,000 shares. All vested immediately. This equity package aligns leadership incentives with company performance amid growth pressures.
8-K
Private Placement Funding Boost
Mangoceuticals raised $1,100,000 through a private placement on August 26 and 29, 2025, issuing 709,677 restricted common shares at $1.55 each to five accredited investors. The deal grants one-year piggyback registration rights, bolstering immediate capital access without underwriting fees. Funds are unrestricted for use. Yet dilution looms for existing holders.
10-Q
Q2 FY2025 results
Mangoceuticals posted Q2 revenue of $168.1K, edging up 3.1% y/y from $163.2K yet dipping 15.2% q/q (derived) from Q1's $198.3K, with gross profit climbing to $90.0K from $69.8K y/y on slimmer costs at the related-party pharmacy. Operating losses widened to $5.3M from $2.2M y/y, fueled by $3.1M in stock-based comp and $1.2M in general/admin expenses tied to IP pursuits and distribution deals. Net loss hit $5.4M or $(0.57) per diluted share on 9.98M weighted shares, versus $2.4M or $(1.37) last year; the gap stems mainly from stock comp exceeding 20% of operating loss. Cash edged to $101K from $59K y/y, propped by $3.6M in financing like stock sales and notes, while free cash flow stays undisclosed in the 10-Q. Debt sits at $700K including a $500K convertible note and $100K related-party loan, with $160.7K owed on patent buys. Investors eye regulatory hurdles around compounded drugs.
8-K
MSA Termination and Share Cancellation
Mangoceuticals terminated its March 2025 Master Distribution Agreement with Navy Wharf on July 30, 2025, rescinding exclusive U.S. and Canada rights to the Diabetinol nutraceutical for blood glucose management and canceling the 1,000,000 restricted common shares issued as consideration. Mutual releases cleared all obligations without penalties, while Navy Wharf's key representations survive. No revenue-sharing follows. Deal unwound cleanly.
8-K
Amends insider note, issues warrants
Mangoceuticals amended its $100,000 convertible promissory note with CEO-controlled Tiger Cub Trust on July 21, 2025, setting a $1.785 conversion price into up to 66,107 shares including $18,000 accrued interest through maturity, while granting warrants for 50,000 shares at $1.815 exercisable until 2028. This insider tweak removes mandatory prepayment on qualified funding, easing capital flexibility amid ongoing needs. On June 10, the firm raised $409,367 net via its ELOC by issuing 261,667 shares at $1.564458 each. Related-party terms heighten dilution risks.
IPO
Employees
Sector
Industry
BRGX
BioRegenx, Inc
0.01-0.01
GDRX
GoodRx Holdings, Inc.
3.66-0.11
HIMS
Hims & Hers Health, Inc.
47.12-1.11
LFMD
LifeMD, Inc.
6.15+0.01
MAJI
Marijuana Inc.
0.11+0.01
MGRM
Monogram Technologies Inc.
6.00+0.00
MNDR
Mobile-health Network Solutions
2.98+0.04
MRMD
MariMed Inc.
0.13-0.01
TDOC
Teladoc Health, Inc.
8.36-0.65
WGRX
Wellgistics Health, Inc.
0.65-0.17